Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) Insider Austin Gurney sold 4,000 shares of the stock on the open market in a transaction dated Friday, August 22nd. The shares were sold at an average price of $20.00, for a total transaction of $80,000.00. Following the sale, the insider now directly owns 97,532 shares in the company, valued at approximately $1,950,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 1.95% on Monday, hitting $19.58. The stock had a trading volume of 127,224 shares. Oncomed Pharmaceuticals has a 52 week low of $12.07 and a 52 week high of $42.34. The stock has a 50-day moving average of $20.7 and a 200-day moving average of $26.30. The company’s market cap is $582.7 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last released its earnings data on Thursday, August 7th. The company reported ($0.53) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. On average, analysts predict that Oncomed Pharmaceuticals will post $-1.35 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on OMED shares. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.